TAMs are capable of enhancing migration of prostate cancer cells via their secretion of various cytokines such as CCL5 and CCL2 while simultaneous activation of enzymes including TRAP5b grants access to new areas of the body, e.g., bones. Here, CCL2 is linked to prostate carcinoma.